Engraftment Efficiency after Intra-Bone Marrow versus Intravenous Transplantation of Bone Marrow Cells in a Canine Nonmyeloablative Dog Leukocyte Antigen-Identical Transplantation Model
IBM application of HSC in a volume up to 25 mL is feasible in a canine model. IBM-injected cells remain in the injected bone but migrate also to other bones. IBM infusion might be superior for early engraftment compared with i.v. application. Method of graft processing seems to be important for successful engraftment in IBM HSCT.